Monte Rosa Therapeutics Inc

NASDAQ GLUE

Data sourced from

and

Daily

Download Data

Monte Rosa Therapeutics Inc Price to Book Ratio (P/B) on June 03, 2024: 1.60

Monte Rosa Therapeutics Inc Price to Book Ratio (P/B) is 1.60 on June 03, 2024, a 6.36% change year over year. The price to book ratio compares the market price per share of a company's stock to its book value per share. It is calculated by dividing the market capitalization by the shareholders' equity minus treasury stock, divided by the number of outstanding shares. This ratio provides insights into how the market values a company relative to its book value. A ratio above 1 indicates the market values the company more than its book value, suggesting positive market sentiment.

Monte Rosa Therapeutics Inc 52-week high Price to Book Ratio (P/B) is 2.37 on March 25, 2024, which is 48.34% above the current Price to Book Ratio (P/B).
Monte Rosa Therapeutics Inc 52-week low Price to Book Ratio (P/B) is 0.00 on March 11, 2024, which is -99.90% below the current Price to Book Ratio (P/B).
Monte Rosa Therapeutics Inc average Price to Book Ratio (P/B) for the last 52 weeks is 1.44.

NASDAQ: GLUE

Monte Rosa Therapeutics Inc

CEO	Dr. Markus Warmuth M.D.
IPO Date	June 24, 2021
Location	United States
Headquarters	645 Summer Street, Boston, MA, United States, 02210
Employees	130
Sector	Healthcare
Industry	Biotechnology

Description

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1"/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Key trends